Research progress on the inflammatory and immune mechanisms of renal damage in anti-neutrophil cytoplasmic antibody-associated vasculitis

doi:10.3877/cma.j.issn.2095-3216.2022.02.010

Abstract

Abstract:

Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is a systemic autoimmune disease that most often involves small blood vessels in the kidneys, causing inflammation, necrosis, and granulomatous infiltration of glomeruli and arterioles, resulting in the renal damage in AAV. The pathogenesis of renal damage in AAV is very complex and has not yet been fully elucidated, the most prominent pathological feature of which is inflammation involving activation of neutrophils, the alternative pathway of complement, and the interaction of other immune cells. This article reviewed research progress on the inflammatory and immune mechanisms of renal damage in AAV.

Key words: Anti-neutrophil cytoplasmic antibody, ANCA-associated vasculitis, Renal damage, Inflammation, Immune

Yiqin Chen, Xiaoxuan Hu, Haijing Hou, Yueyu Gu, Xusheng Liu, Fuhua Lu. Research progress on the inflammatory and immune mechanisms of renal damage in anti-neutrophil cytoplasmic antibody-associated vasculitis[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2022, 11(02): 104-108.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2022.02.010

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2022/V11/I02/104

Figures/Tables 2

References 34

[1]	Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides [J]. Arthritis Rheum, 2013, 65(1): 1-11.
[2]	Gibson KM, Kain R, Luqmani RA, et al. Autoantibodies against lysosome associated membrane protein-2 (LAMP-2) in pediatric chronic primary systemic vasculitis [J]. Front Immunol, 2020, 11: 624758.
[3]	Kimura H, Matsuyama Y, Araki S, et al. The effect and possible clinical efficacy of in vivo inhibition of neutrophil extracellular traps by blockade of PI3K-gamma on the pathogenesis of microscopic polyangiitis [J]. Mod Rheumatol, 2018, 28(3): 530-541.
[4]	Chen M, Yu F, Wang SX, et al. Antineutrophil cytoplasmic autoantibody-negative pauci-immune crescentic glomerulonephritis [J]. J Am Soc Nephrol, 2007, 18(2): 599-605.
[5]	Ohlsson S, Holm L, Hansson C, et al. Neutrophils from ANCA-associated vasculitis patients show an increased capacity to activate the complement system via the alternative pathway after ANCA stimulation [J]. PLoS One, 2019, 14(6): e0218272.
[6]	Chen M, Jayne DRW, Zhao MH. Complement in ANCA-associated vasculitis: mechanisms and implications for management [J]. Nat Rev Nephrol, 2017, 13(6): 359-367.
[7]	魏丹丹，林旭红，白春洋. FcγRⅡa及相关炎症分子在ANCA相关性血管炎中的意义[J]. 现代预防医学，2014, 41(22): 4184-4185, 4196.
[8]	Nakazawa D, Masuda S, Tomaru U, et al. Pathogenesis and therapeutic interventions for ANCA-associated vasculitis [J]. Nat Rev Rheumatol, 2019, 15(2): 91-101.
[9]	Wang H, Wang C, Zhao MH, et al. Neutrophil extracellular traps can activate alternative complement pathways [J]. Clin Exp Immunol, 2015, 181(3): 518-527.
[10]	贾庆龄. 中性粒细胞胞外诱捕网激活单核细胞在ANCA相关性血管炎的作用[D]. 重庆：第三军医大学，2017.
[11]	Lee KH, Kronbichler A, Park DD, et al. Neutrophil extracellular traps (NETs) in autoimmune diseases: a comprehensive review [J]. Autoimmun Rev, 2017, 16(11): 1160-1173.
[12]	Choi H, Kim Y, Jung SM, et al. Low serum complement 3 level is associated with severe ANCA-associated vasculitis at diagnosis [J]. Clin Exp Nephrol, 2019, 23(2): 223-230.
[13]	Wu EY, McInnis EA, Boyer-Suavet S, et al. Measuring circulating complement activation products in myeloperoxidase- and proteinase 3-antineutrophil cytoplasmic antibody-associated vasculitis [J]. Arthritis Rheumatol, 2019, 71(11): 1894-1903.
[14]	Ort M, Dingemanse J, van den Anker J, et al. Treatment of rare inflammatory kidney diseases: drugs targeting the terminal complement pathway [J]. Front Immunol, 2020, 11: 599417.
[15]	Wester Trejo MAC, Trouw LA, Bajema IM. The role of complement in antineutrophil cytoplasmic antibody-associated vasculitis [J]. Curr Opin Rheumatol, 2019, 31(1): 3-8.
[16]	Dick J, Gan PY, Ford SL, et al. C5a receptor 1 promotes autoimmunity, neutrophil dysfunction and injury in experimental anti-myeloperoxidase glomerulonephritis [J]. Kidney Int, 2018, 93(3): 615-625.
[17]	Finsterbusch M, Hall P, Li A, et al. Patrolling monocytes promote intravascular neutrophil activation and glomerular injury in the acutely inflamed glomerulus [J]. Proc Natl Acad Sci USA, 2016, 113(35): E5172-E5181.
[18]	Popat RJ, Hakki S, Thakker A, et al. Anti-myeloperoxidase antibodies attenuate the monocyte response to LPS and shape macrophage development [J]. JCI Insight, 2017, 2(2): e87379.
[19]	Tang PM, Nikolic-Paterson DJ, Lan HY. Macrophages: versatile players in renal inflammation and fibrosis [J]. Nat Rev Nephrol, 2019, 15(3): 144-158.
[20]	Nakazawa D, Marschner JA, Platen L, et al. Extracellular traps in kidney disease [J]. Kidney Int, 2018, 94(6): 1087-1098.
[21]	Gao Z, Gao Y, Li Z, et al. Synergy between IL-6 and TGF-β signaling promotes FOXP3 degradation [J]. Int J Clin Exp Pathol, 2012, 5(7): 626-633.
[22]	Yang C, Huang XR, Fung E, et al. The regulatory t-cell transcription factor Foxp3 protects against crescentic glomerulonephritis [J]. Sci Rep, 2017, 7(1): 1481.
[23]	Casal Moura M, Irazabal MV, Eirin A, et al. Efficacy of rituximab and plasma exchange in antineutrophil cytoplasmic antibody-associated vasculitis with severe kidney disease [J]. J Am Soc Nephrol, 2020, 31(11): 2688-2704.
[24]	Dolff S, Witzke O, Wilde B. Th17 cells: do regulatory B-cells (Breg) take control in ANCA-vasculitis? [J]. Rheumatology (Oxford), 2019, 58(8): 1329-1330.
[25]	Kronbichler A, Lee KH, Denicolò S, et al. Immunopathogenesis of ANCA-associated vasculitis [J]. Int J Mol Sci, 2020, 21(19): 7319.
[26]	Huugen D, Tervaert JW, Heeringa P. TNF-alpha bioactivity-inhibiting therapy in ANCA-associated vasculitis: clinical and experimental considerations [J]. Clin J Am Soc Nephrol, 2006, 1(5): 1100-1107.
[27]	Karras A, Lazareth H, Chauvet S. B-cell treatment in ANCA-associated vasculitis [J]. Rheumatology (Oxford), 2020, 59(Suppl 3): iii68-iii73.
[28]	Wang C, Chang DY, Chen M, et al. HMGB1 contributes to glomerular endothelial cell injury in ANCA-associated vasculitis through enhancing endothelium-neutrophil interactions [J]. J Cell Mol Med, 2017, 21(7): 1351-1360.
[29]	Cortvrindt C, Speeckaert R, Moerman A, et al. The role of interleukin-17A in the pathogenesis of kidney diseases [J]. Pathology, 2017, 49(3): 247-258.
[30]	Li ZY, Ma TT, Chen M, et al. The prevalence and management of anti-neutrophil cytoplasmic antibody-associated vasculitis in China [J]. Kidney Dis (Basel), 2016, 1(4): 216-223.
[31]	Wechsler ME, Akuthota P, Jayne D, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis [J]. N Engl J Med, 2017, 376(20): 1921-1932.
[32]	Jayne DRW, Bruchfeld AN, Harper L, et al. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis [J]. J Am Soc Nephrol, 2017, 28(9): 2756-2767.
[33]	Sakai R, Kondo T, Kurasawa T, et al. Current clinical evidence of tocilizumab for the treatment of ANCA-associated vasculitis: a prospective case series for microscopic polyangiitis in a combination with corticosteroids and literature review [J]. Clin Rheumatol, 2017, 36(10): 2383-2392.
[34]	Walsh M, Merkel PA, Peh CA, et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis [J]. N Engl J Med, 2020, 382(7): 622-631.

Please choose a citation manager

Content to export